Evaluation of the Efficacy of Kallikrein Inhibition by Lanadelumab for Patients With Bradykinin Angioedema: a Cohort Study
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
A multicenter observational study aiming to evaluate the efficacy of kallikrein inhibition by lanadelumab in patients with bradykinin- angioedema
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male/female \>18 years old
• Patient with hereditary or acquired angioedema
• Patient treated by lanadelumab
• Patient whose the biological explorations have been carried out or will be carried out at Laboratory of Immunology of CHUGA
• Informed consent is obtained from the participant
Locations
Other Locations
France
Chu Grenoble Alpes
RECRUITING
Grenoble
CHU Rouen
RECRUITING
Rouen
Contact Information
Primary
Federica Defendi, PhD
fdefendi@chu-grenoble.fr
+330476765416
Backup
Charlotte Kevorkian-Verguet
ckevorkian-verguet@chu-grenoble.fr
+330476765416
Time Frame
Start Date: 2020-09-18
Estimated Completion Date: 2025-09
Participants
Target number of participants: 80
Treatments
Participants with Hereditary or Acquired Angioedema
Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Grenoble